Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer

CONCLUSIONS: Combination of olaparib and capivasertib is associated to no serious adverse events and demonstrates durable activity in ovarian, endometrial and breast cancers, with promising responses in endometrial cancer. Importantly, tumor samples acquired pre- and on-therapy can help predict patient benefit.PMID:34518313 | DOI:10.1158/1078-0432.CCR-21-1656

Source: Clinical Breast Cancer - September 14, 2021 Category: Cancer & Oncology Authors: Shannon N Westin Marilyne Labrie Jennifer K Litton Aurora Blucher Yong Fang Christopher P Vellano Joseph R Marszalek Ningping Feng Xiaoyan Ma Allison Creason Bryan Fellman Ying Yuan Sanghoon Lee TaeBeom Kim Jinsong Liu Anca Chelariu-Raicu Tsun Hsuan Chen Source Type: research